STOCK TITAN
  1. Home
  2. News
  3. AUTL

Autolus Therapeutics plc - AUTL STOCK NEWS

Welcome to our dedicated news page for Autolus Therapeutics plc (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Autolus Therapeutics plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Autolus Therapeutics plc's position in the market.

News
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Rhea-AI Summary
Autolus Therapeutics plc announces the selection of the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL for an oral presentation at ASCO 2024. The presentation will cover overall survival, event-free survival, CAR-T cell persistency, and consolidative stem cell transplantation. Dr. Elias Jabbour will be the presenting author.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
clinical trial
-
News
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Rhea-AI Summary
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its first quarter 2024 financial results and operational highlights on May 14, 2024. The company will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
News
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Rhea-AI Summary
Autolus Therapeutics plc announces the acceptance of the Marketing Authorization Application (MAA) for obe-cel by the European Medicines Agency (EMA), based on data from the pivotal Phase 2 FELIX study in adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL). The company's lead investigational CAR T cell therapy, obe-cel, has received various designations and certifications, including Orphan Drug Designation by the FDA and RMAT designation by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
none
News
Autolus Therapeutics Announces Changes to its Board of Directors
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) appoints Mike Bonney as Chairman of the Board and Ravi Rao M.D. as Non-Executive Director, effective April 1, 2024. The company expresses gratitude to John H. Johnson for his leadership during key milestones. Mike Bonney brings extensive biotech and pharmaceutical experience, previously leading Cubist Pharmaceuticals, while Dr. Ravi Rao has a strong background in clinical development. These appointments signal Autolus' strategic focus on growth and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.97%
Tags
management
-
News
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Rhea-AI Summary
Autolus Therapeutics plc announces strategic collaboration and equity investment from BioNTech, submits BLA for obecabtagene autoleucel, and completes underwritten offering of ADSs. Financial results show increased expenses and net loss for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
earnings
-
News
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) has received Manufacturer’s Importation Authorisation for its Nucleus manufacturing facility, allowing global commercial and clinical product supply. The MHRA issued licenses with no major observations, enhancing Autolus' capabilities for autologous cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
News
Autolus Therapeutics announces publication in Blood Cancer Journal
Rhea-AI Summary
Autolus Therapeutics plc announced a breakthrough publication in Blood Cancer Journal regarding the identification of T-cell neoplasms using a new flow cytometry method. The company collaborates with Mayo Clinic to introduce a unique approach utilizing TRBC1 and TRBC2 antibodies. This innovative strategy aims to simplify the detection of clonal expansion in T-cells, potentially revolutionizing diagnostic panels and enhancing therapeutic strategies for T-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
-
News
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) will announce its Q4 and full year 2023 results on March 14, 2024. The company will host a conference call to discuss financial results and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences earnings
-
News
Autolus Therapeutics announces publication in Nature Communications 
Rhea-AI Summary
Autolus Therapeutics plc announces the development of TRBC1 and TRBC2-targeting immunotherapies for T cell lymphomas, introducing AUTO4 and AUTO5 CAR T cell therapies. Early clinical data from the LibraT1 study shows promising results. The publication in Nature Communications highlights the structural basis for selective CAR recognition of TRBC1 and TRBC2, paving the way for potential broad therapeutic approaches in T cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
News
Autolus Announces Pricing of Underwritten Offering
Rhea-AI Summary
Autolus Therapeutics plc (AUTL) has announced the pricing of an underwritten offering of 58,333,336 American Depositary Shares (ADSs) at a public offering price of $6.00 per ADS, for total gross proceeds of $350 million. The company intends to use the net proceeds to advance the clinical development of its obe-cel program, fund manufacturing activities, develop its commercial infrastructure, and for other general corporate purposes. The offering is expected to close on February 12, 2024, and is being managed by Jefferies LLC and Truist Securities, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
none
Stock AUTL logo
Autolus Therapeutics plc

Nasdaq:AUTL

AUTL Rankings

#2350 Ranked by Market Cap
#2489 Ranked by Stock Gains
N/A Ranked by Dividends

AUTL Stock Data

1.29B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United Kingdom
58 Wood Lane

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.